Screener
Amgen AMGN Business Segments — Royalty Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 10,054 | 9,179 | 18,672 | 17,328 |
| Less: | ||||
| Manufacturing cost of sales(1)(2) | 2,139 | 2,484 | 4,319 | 5,012 |
| Profit share and royalties in cost of sales(1) | 672 | 527 | 1,236 | 967 |
| Research and development(1) | 1,868 | 1,744 | 3,587 | 3,230 |
| Sales and marketing(1) | 1,155 | 1,137 | 2,289 | 2,203 |
| General and administrative(1) | 590 | 554 | 1,058 | 1,175 |
| Other segment items(3) | 314 | 557 | 227 | (5) |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's business segments — royalty expense?
- Amgen (AMGN) reported business segments — royalty expense of $672M in Q2 2026.
- How has Amgen's business segments — royalty expense changed year-over-year?
- Amgen's business segments — royalty expense increased by 27.5% year-over-year, from $527M to $672M.
- What does business segments — royalty expense mean?
- Represents payments made to third parties for the use of intellectual property, patents, or licensed technologies incorporated into the company's drug portfolio. These expenses are contractual obligations that directly impact the profitability of specific therapeutic products. High royalty burdens can significantly influence the net margin of licensed assets.
Ask your AI about Amgen's business segments — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude